Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities

Since the late 1990s, there have been tremendous strides made in improving the capacity for carrying out routine active surveillance of new vaccines in the United States. These strides have led to new surveillance systems that are now in place. Some of the critical elements that are part of successful vaccine or drug safety surveillance systems include their use of (i) longitudinal data from a discrete enumerated population base, (ii) frequent, routine transfers of small amounts of data that are easy to collect and collate, (iii) avoidance of mission creep, (iv) statistical capabilities, (v) creation of an “industrialized process” approach and (vi) political safe harbor.

[1]  Peter Vedsted,et al.  Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. , 2012, JAMA.

[2]  Steven J. Jacobsen,et al.  The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.

[3]  W Katherine Yih,et al.  Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project , 2011, Pediatrics.

[4]  Weizhong Yang,et al.  Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. , 2011, The New England journal of medicine.

[5]  M. Kulldorff,et al.  A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance , 2011 .

[6]  Barbara Goodson,et al.  Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism , 2010, Pediatrics.

[7]  W Katherine Yih,et al.  Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures , 2010, Pediatrics.

[8]  D. Snider,et al.  Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  W Katherine Yih,et al.  Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine , 2010, The Pediatric infectious disease journal.

[10]  W Katherine Yih,et al.  An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. , 2009, Vaccine.

[11]  R. Reading.  Risk of immune thrombocytopenic purpura after measles‐mumps‐rubella immunization in children , 2008 .

[12]  Robert T. Chen,et al.  Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children , 2008, Pediatrics.

[13]  Robert L Davis,et al.  Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.

[14]  R. Davis,et al.  Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. , 2007, The New England journal of medicine.

[15]  B. Schwartz,et al.  Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine , 2007, Pediatrics.

[16]  J. Clemens,et al.  The use of a computerized database to monitor vaccine safety in Viet Nam. , 2005, Bulletin of the World Health Organization.

[17]  O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  Robert T. Chen,et al.  Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events , 2005, Epidemiology.

[19]  Susan S Ellenberg,et al.  Evaluating the safety of new vaccines: summary of a workshop. , 2005, American journal of public health.

[20]  Richard Horton,et al.  Vioxx, the implosion of Merck, and aftershocks at the FDA , 2004, The Lancet.

[21]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[22]  D. Skowronski,et al.  Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Robert T. Chen,et al.  Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. , 2003, Morbidity and mortality weekly report. Surveillance summaries.

[24]  John W. Glasser,et al.  The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. , 2001, The New England journal of medicine.

[25]  Robert T. Chen,et al.  Population-based study of rotavirus vaccination and intussusception , 2001, The Pediatric infectious disease journal.

[26]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[27]  Jun Li,et al.  Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association , 1999, The Lancet.

[28]  R. Glass,et al.  Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1999 .

[29]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[30]  B. Levine,et al.  Combination measles, mumps, rubella and varicella vaccine. , 1986, Pediatrics.

[31]  A. Mack.  Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism , 2011 .

[32]  Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[33]  G. Garnett,et al.  ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES , 2006 .

[34]  B. Schwartz,et al.  Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics. , 1998, Pediatrics.

[35]  R. Harpaz,et al.  Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.